Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HERAMED LIMITED Call Transcript 2020

Dec 16, 2020

65062_rns_2020-12-16_673449fa-881c-4fd5-b812-3ab68875c561.pdf

Call Transcript

Open in viewer

Opens in your device viewer

17 December 2020

==> picture [593 x 56] intentionally omitted <==

ASX ANNOUNCEMENT

HeraMED Investor Update Conference Call

HeraMED Limited (ASX: HMD) (“HeraMED” or the “Company”), a medical data and technology company leading the digital transformation of maternity care with its proprietary in-home maternity care platform, will host a conference call on Friday 18 December 2020 at 10:30 AEDT (Sydney/Melbourne), 7:30 AWST (Perth) to update shareholders on the recent announcements.

The call will be hosted by David Groberman, CEO and Co-founder and Alex Radke , US General Manager of Operations.

During the call, David and Alex will discuss the results of the recent progress made on its commercialisation strategy.

Conference call details:

Date: Friday 18 December 2020 Time: 10:30am (Sydney/Melbourne) / 7:30am (Perth) To register: https://s1.c-conf.com/diamondpass/10011537-d8skzl.html Dial in details: You will receive your personal dial in details upon registration

The Company welcomes questions at the end of the conference call. To ask a question, please press *1 (star 1) on your telephone keypad.

-ENDS-

This announcement was authorised by the Board of HeraMED Limited.

HeraMED Limited Company Secretary Media Enquiries CEO and Co-Founder Jonathan Hart Melissa Hamilton David Groberman T: +61 2 8379 2961 Media and Capital Partners M: +972 52 699 1188 E: [email protected] M: +61 4 1775 0274 E: [email protected] E: [email protected]

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical date and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, big data, and a digital social networking dashboard.

HeraMED Limited ACN 626 295 314 T: +61 2 8379 2961 | A: Suite 3, Level 10 23-25 Hunter St, Sydney NSW 2000

1